Completed NA INTERVENTIONAL 1-arm NCT02688829

The First-In-Man Pilot Study of Firehawk

The Initial Small-Scale Clinical Study of Rapamycin-Eluting Coronary Stent System of Microport (Firehawk)

Sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.

Interventions Rapamycin target-eluting Coronary Stent System

Updated 8 times since 2017 Last updated: Sep 26, 2019 Started: Dec 31, 2009 Primary completion: Jan 31, 2010 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Coronary Heart Disease, this trial is completed. The trial is conducted by Shanghai MicroPort Medical (Group) Co., Ltd. and has accumulated 8 data snapshots since 2009. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2023 — Jul 2024 [monthly]

Completed NA
Dec 2022 — Jan 2023 [monthly]

Completed NA
Jan 2021 — Dec 2022 [monthly]

Completed NA

▶ Show 3 earlier versions

Nov 2019 — Jan 2021 [monthly]

Completed NA
Jul 2019 — Nov 2019 [monthly]

Completed NA
Jan 2017 — Jul 2019 [monthly]

Completed NA

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai MicroPort Medical (Group) Co., Ltd.

Data source: Shanghai MicroPort Medical (Group) Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.